IMTX saw its Momentum Indicator move above the 0 level on October 20, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 91 similar instances where the indicator turned positive. In 70 of the 91 cases, the stock moved higher in the following days. The odds of a move higher are at 77%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where IMTX's RSI Oscillator exited the oversold zone, 24 of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.
The Moving Average Convergence Divergence (MACD) for IMTX just turned positive on October 21, 2026. Looking at past instances where IMTX's MACD turned positive, the stock continued to rise in 36 of 50 cases over the following month. The odds of a continued upward trend are 72%.
Following a +9.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where IMTX advanced for three days, in 221 of 289 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
IMTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for IMTX entered a downward trend on October 14, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 22 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.872) is normal, around the industry mean (2.973). P/E Ratio (-4.742) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (23.202) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. IMTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where PTCT advanced for three days, in 223 of 280 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where PTCT's RSI Oscillator exited the oversold zone, 21 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 46 of 60 cases where PTCT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Moving Average Convergence Divergence (MACD) for PTCT just turned positive on October 20, 2026. Looking at past instances where PTCT's MACD turned positive, the stock continued to rise in 34 of 44 cases over the following month. The odds of a continued upward trend are 77%.
PTCT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on October 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PTCT as a result. In 71 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
The 50-day moving average for PTCT moved below the 200-day moving average on September 18, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PTCT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.
The Aroon Indicator for PTCT entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 1 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-31.605) is normal, around the industry mean (2.988). PTCT has a moderately low P/E Ratio (-93.463) as compared to the industry average of (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (6.094) is also within normal values, averaging (438.009).
The Tickeron Profit vs. Risk Rating rating for this company is 65 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 71 (best 1 - 100 worst), indicating slightly worse than average price growth. PTCT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
IMTX | PTCT | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 31 | 74 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 30 Undervalued | 1 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 65 | |
SMR RATING 1..100 | 98 | 100 | |
PRICE GROWTH RATING 1..100 | 78 | 71 | |
P/E GROWTH RATING 1..100 | 22 | 100 | |
SEASONALITY SCORE 1..100 | 90 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
PTCT's Valuation (1) in the Biotechnology industry is in the same range as IMTX (30) in the null industry. This means that PTCT’s stock grew similarly to IMTX’s over the last 12 months.
PTCT's Profit vs Risk Rating (65) in the Biotechnology industry is somewhat better than the same rating for IMTX (100) in the null industry. This means that PTCT’s stock grew somewhat faster than IMTX’s over the last 12 months.
IMTX's SMR Rating (98) in the null industry is in the same range as PTCT (100) in the Biotechnology industry. This means that IMTX’s stock grew similarly to PTCT’s over the last 12 months.
PTCT's Price Growth Rating (71) in the Biotechnology industry is in the same range as IMTX (78) in the null industry. This means that PTCT’s stock grew similarly to IMTX’s over the last 12 months.
IMTX's P/E Growth Rating (22) in the null industry is significantly better than the same rating for PTCT (100) in the Biotechnology industry. This means that IMTX’s stock grew significantly faster than PTCT’s over the last 12 months.
| IMTX | PTCT | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 75% | 2 days ago 78% |
| Stochastic ODDS (%) | 1 day ago 86% | 2 days ago 77% |
| Momentum ODDS (%) | 1 day ago 77% | 2 days ago 84% |
| MACD ODDS (%) | 1 day ago 72% | 2 days ago 77% |
| TrendWeek ODDS (%) | 1 day ago 78% | 2 days ago 78% |
| TrendMonth ODDS (%) | 1 day ago 83% | 2 days ago 75% |
| Advances ODDS (%) | 2 days ago 76% | 3 days ago 80% |
| Declines ODDS (%) | 10 days ago 85% | 9 days ago 78% |
| BollingerBands ODDS (%) | 1 day ago 74% | 2 days ago 78% |
| Aroon ODDS (%) | 1 day ago 84% | 2 days ago 73% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
IMTX’s FA Score shows that 2 FA rating(s) are green while PTCT’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
IMTX’s TA Score shows that 6 TA indicator(s) are bullish while PTCT’s TA Score has 5 bullish TA indicator(s).
IMTX (@Biotechnology) experienced а +9.86% price change this week, while PTCT (@Biotechnology) price change was +4.94% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.
IMTX is expected to report earnings on Nov 16, 2026.
PTCT is expected to report earnings on Oct 29, 2026.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
A.I.dvisor indicates that over the last year, IMTX has been loosely correlated with SLDB. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if IMTX jumps, then SLDB could also see price increases.
| Ticker / NAME | Correlation To IMTX | 1D Price Change % | ||
|---|---|---|---|---|
| IMTX | 100% | -1.95% | ||
| SLDB - IMTX | 53% Loosely correlated | -3.43% | ||
| VIR - IMTX | 48% Loosely correlated | -1.32% | ||
| ABEO - IMTX | 47% Loosely correlated | -0.89% | ||
| CELC - IMTX | 47% Loosely correlated | +6.51% | ||
| TSHA - IMTX | 46% Loosely correlated | -2.79% | ||
More | ||||